The Museum Tinguely, which was founded in 1996 and is dedicated to the work of the Swiss metal sculptor Jean Tinguely, is a cultural commitment by Roche.
In addition to its permanent exhibition of the machine sculptures and graphic works of Jean Tinguely, who died in 1991, the museum also hosts special exhibitions that give an insight into the art and artists who influenced and were associated with Tinguely, kinetic art and 20th and 21st-century art. Current and past exhibitions have been dedicated to such friends and partners of Tinguely as Niki de Saint Phalle, Yves Klein or Eva Aeppli; to role models such as Marcel Duchamp, Kurt Schwitters or Max Ernst; and to more recent trends such as contemporary kinetic art. Exhibitions always focus on new areas of art. Further information on the Museum Tinguely can be found on its website www.tinguely.ch.
Offbeat Concert GmbH is delighted to be creating the concert programme for the popular Roche'n'Jazz holiday evening concerts from 29.10. to 29.4.2022.
Offbeat aims to present atmospheric and contemporary jazz projects at the Museum Tinguely, creating a synergetic effect of visual art and improvised music. In 6 concerts on the last Friday of each month, top musicians and current bands of Swiss and international jazz are presented exclusively. Offbeat, which has been present in Basel for 32 years with the Jazz Festival Basel and with many season star concerts, would like to thank you for your trust in the offbeat brand.
For more information about the bird's eye, please visit the homepage https://www.offbeat-concert.ch/.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims for improving patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law.